Bio Innovation is
Our Mission
We are biotechnology pharmaceutical company focusing on antibody and bacteriophage therapies to address unmet medical needs.
Our cutting-edge research aims to develop novel treatments for resistant infections and complex diseases, providing new hope for patients.
Diabetic
Retinophaty
Ocular Surface Infection
Diabetic Foot
Infection
Atopic
Dermatitis
Respiratory
Infection
Our Goals
.jpeg)
.jpeg)
Our Technology
Our advanced technology platform is driving innovation in antibody and bacteriophage therapies to meet critical unmet medical needs. By leveraging the precision of engineered antibodies and the unique capabilities of bacteriophages, we are developing targeted treatments to resistant infections and complex diseases.
Our technologies enable us to design highly specific, effective, and safe therapeutic solutions, pushing the boundaries of modern medicine and transforming patient care.
Welcome to Lxbio, where the future of biopharmaceuticals is being redefined. As a newly established pharmaceutical company, we present a compelling opportunity for investors seeking to be at the forefront of groundbreaking innovation in the global biopharmaceutical market.
Invest with us
News
(1)_edited.png)
Lxbio Pharmaceuticals (Identificar página @Lxbio Pharmaceuticals) is pleased to announce that an investment agreement has been signed with Explorer SCR (Identificar página @Explorer Investments), a leading investment Fund in Portugal, an investment with a global amount of 6 Million Euros, namely, to support Lxbio research & development projects.
(1)_edited.png)
We are thrilled to announce the location of our new state-of-the-art biotechnology manufacturing facility and new R&D site, a significant milestone in our journey towards redefining the landscape of biotechnological innovation.
Last month TechnoPhage, founding partner and shareholder of Lxbio, attended ECCMID 2023. Together with the clinical team from Israel, it was presented the results from two cases of compassionate use carried out in Israel, under the supervision of Dra. Michal Deckel.